Skip to main content
. Author manuscript; available in PMC: 2015 Apr 8.
Published in final edited form as: Cancer. 2013 May 29;119(17):3148–3155. doi: 10.1002/cncr.28144

Figure 5.

Figure 5

Kaplan-Meier log-rank survival analysis for mixed lineage kinase domain-like protein (MLKL) expression is shown in patients receiving gemcitabine therapy (n = 32). (A) The effect of MLKL expression on recurrence-free survival is shown. (B) The effect of MLKL expression on overall survival is shown.